299 related articles for article (PubMed ID: 23784380)
1. Inflammatory breast cancer (IBC): clues for targeted therapies.
Fernandez SV; Robertson FM; Pei J; Aburto-Chumpitaz L; Mu Z; Chu K; Alpaugh RK; Huang Y; Cao Y; Ye Z; Cai KQ; Boley KM; Klein-Szanto AJ; Devarajan K; Addya S; Cristofanilli M
Breast Cancer Res Treat; 2013 Jul; 140(1):23-33. PubMed ID: 23784380
[TBL] [Abstract][Full Text] [Related]
2. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
Salem I; Alsalahi M; Chervoneva I; Aburto LD; Addya S; Ott GR; Ruggeri BA; Cristofanilli M; Fernandez SV
Breast Cancer Res; 2016 Mar; 18(1):37. PubMed ID: 27009091
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
4. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity.
Rypens C; Marsan M; Van Berckelaer C; Billiet C; Melis K; Lopez SP; van Dam P; Devi GR; Finetti P; Ueno NT; Bertucci F; Dirix P; Neven P; Vermeulen P; Dirix L; Van Laere SJ
Breast Cancer Res Treat; 2020 Apr; 180(2):385-395. PubMed ID: 32043194
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model.
Lacerda L; Debeb BG; Smith D; Larson R; Solley T; Xu W; Krishnamurthy S; Gong Y; Levy LB; Buchholz T; Ueno NT; Klopp A; Woodward WA
Breast Cancer Res; 2015 Mar; 17(1):42. PubMed ID: 25887413
[TBL] [Abstract][Full Text] [Related]
7. Modeling and characterization of inflammatory breast cancer emboli grown in vitro.
Lehman HL; Dashner EJ; Lucey M; Vermeulen P; Dirix L; Van Laere S; van Golen KL
Int J Cancer; 2013 May; 132(10):2283-94. PubMed ID: 23129218
[TBL] [Abstract][Full Text] [Related]
8. Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.
Eckhardt BL; Gagliardi M; Iles L; Evans K; Ivan C; Liu X; Liu CG; Souza G; Rao A; Meric-Bernstam F; Ueno NT; Bartholomeusz GA
PLoS One; 2018; 13(5):e0195932. PubMed ID: 29768500
[TBL] [Abstract][Full Text] [Related]
9. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells.
Mu Z; Li H; Fernandez SV; Alpaugh KR; Zhang R; Cristofanilli M
J Exp Clin Cancer Res; 2013 Sep; 32(1):70. PubMed ID: 24294976
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication.
Kim MH; Lee S; Koo JS; Jung KH; Park IH; Jeong J; Kim SI; Park S; Park HS; Park BW; Kim JH; Sohn J
PLoS One; 2015; 10(3):e0120320. PubMed ID: 25803816
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network.
Valeta-Magara A; Gadi A; Volta V; Walters B; Arju R; Giashuddin S; Zhong H; Schneider RJ
Cancer Res; 2019 Jul; 79(13):3360-3371. PubMed ID: 31043378
[TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells.
Mineva ND; Paulson KE; Naber SP; Yee AS; Sonenshein GE
PLoS One; 2013; 8(9):e73464. PubMed ID: 24039951
[TBL] [Abstract][Full Text] [Related]
13. Role of adipose tissue-derived cytokines in the progression of inflammatory breast cancer in patients with obesity.
Ibrahim AS; El-Shinawi M; Sabet S; Ibrahim SA; Mohamed MM
Lipids Health Dis; 2022 Aug; 21(1):67. PubMed ID: 35927653
[TBL] [Abstract][Full Text] [Related]
14. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
15. Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells.
Cohen EN; Gao H; Anfossi S; Mego M; Reddy NG; Debeb B; Giordano A; Tin S; Wu Q; Garza RJ; Cristofanilli M; Mani SA; Croix DA; Ueno NT; Woodward WA; Luthra R; Krishnamurthy S; Reuben JM
PLoS One; 2015; 10(7):e0132710. PubMed ID: 26207636
[TBL] [Abstract][Full Text] [Related]
16. Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer.
Martínez-Montemayor MM; Acevedo RR; Otero-Franqui E; Cubano LA; Dharmawardhane SF
Nutr Cancer; 2011; 63(7):1085-94. PubMed ID: 21888505
[TBL] [Abstract][Full Text] [Related]
17. E-cadherin accumulation within the lymphovascular embolus of inflammatory breast cancer is due to altered trafficking.
Ye Y; Tellez JD; Durazo M; Belcher M; Yearsley K; Barsky SH
Anticancer Res; 2010 Oct; 30(10):3903-10. PubMed ID: 21036701
[TBL] [Abstract][Full Text] [Related]
18. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
[TBL] [Abstract][Full Text] [Related]
19. PLEKHA7, an Apical Adherens Junction Protein, Suppresses Inflammatory Breast Cancer in the Context of High E-Cadherin and p120-Catenin Expression.
Pence LJ; Kourtidis A; Feathers RW; Haddad MT; Sotiriou S; Decker PA; Nassar A; Ocal IT; Shah SS; Anastasiadis PZ
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525380
[TBL] [Abstract][Full Text] [Related]
20. Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer.
Hu X; Villodre ES; Larson R; Rahal OM; Wang X; Gong Y; Song J; Krishnamurthy S; Ueno NT; Tripathy D; Woodward WA; Debeb BG
Commun Biol; 2021 Jan; 4(1):72. PubMed ID: 33452400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
